FR13C0044I2 - USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF CANINE EPILEPSY - Google Patents

USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF CANINE EPILEPSY

Info

Publication number
FR13C0044I2
FR13C0044I2 FR13C0044C FR13C0044C FR13C0044I2 FR 13C0044 I2 FR13C0044 I2 FR 13C0044I2 FR 13C0044 C FR13C0044 C FR 13C0044C FR 13C0044 C FR13C0044 C FR 13C0044C FR 13C0044 I2 FR13C0044 I2 FR 13C0044I2
Authority
FR
France
Prior art keywords
dihydroimidazolones
treatment
canine epilepsy
canine
epilepsy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0044C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica Gm
Original Assignee
Boehringer Ingelheim Vetmedica Gm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gm filed Critical Boehringer Ingelheim Vetmedica Gm
Publication of FR13C0044I1 publication Critical patent/FR13C0044I1/fr
Application granted granted Critical
Publication of FR13C0044I2 publication Critical patent/FR13C0044I2/en
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR13C0044C 2002-10-10 2013-07-24 USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF CANINE EPILEPSY Active FR13C0044I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41759002P 2002-10-10 2002-10-10
PCT/EP2003/011212 WO2004032938A1 (en) 2002-10-10 2003-10-09 Use of dihydroimidazolones for the treatment of epilepsy in dogs

Publications (2)

Publication Number Publication Date
FR13C0044I1 FR13C0044I1 (en) 2013-08-30
FR13C0044I2 true FR13C0044I2 (en) 2014-03-07

Family

ID=32094042

Family Applications (2)

Application Number Title Priority Date Filing Date
FR13C0044C Active FR13C0044I2 (en) 2002-10-10 2013-07-24 USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF CANINE EPILEPSY
FR22C1033C Active FR22C1033I1 (en) 2002-10-10 2022-06-30 Use of dihydroimidazolones for the treatment of dogs

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR22C1033C Active FR22C1033I1 (en) 2002-10-10 2022-06-30 Use of dihydroimidazolones for the treatment of dogs

Country Status (28)

Country Link
US (5) US20050070537A1 (en)
EP (3) EP1553952B1 (en)
JP (4) JP4694202B2 (en)
KR (2) KR20110063843A (en)
CN (2) CN101890019A (en)
AR (1) AR041573A1 (en)
AT (1) ATE418337T1 (en)
AU (2) AU2003273978B2 (en)
BE (1) BE2013C046I2 (en)
BR (1) BR0315225A (en)
CA (2) CA2501772C (en)
CY (3) CY1109961T1 (en)
DE (1) DE60325496D1 (en)
DK (2) DK1553952T3 (en)
ES (2) ES2908453T3 (en)
FR (2) FR13C0044I2 (en)
HK (1) HK1085920A1 (en)
HR (3) HRP20090667B1 (en)
HU (2) HUS1300035I1 (en)
LU (1) LU92238I2 (en)
MX (1) MXPA05003663A (en)
NZ (1) NZ539864A (en)
PL (2) PL214702B1 (en)
PT (2) PT2845594T (en)
SI (2) SI1553952T1 (en)
TW (2) TWI324067B (en)
WO (1) WO2004032938A1 (en)
ZA (1) ZA200502245B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
CN101254189A (en) * 2003-07-11 2008-09-03 埃尔比昂股份公司 Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
BR112014003117A2 (en) 2011-08-12 2017-06-13 Boehringer Ingelheim Vetmedica Gmbh funny (if) current inhibitors for use in a method of treatment and prevention of feline heart failure
JP6193613B2 (en) * 2013-05-10 2017-09-06 学校法人麻布獣医学園 Epilepsy seizure monitoring system and method
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
EP3150598B1 (en) 2014-05-28 2019-02-13 TOA Eiyo Ltd. Substituted tropane derivatives
EP3193862B1 (en) 2014-09-16 2023-10-18 Igc Pharma Ip, Llc Topical cannabinoid composition for treating arthritic pain
CA2974895A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044021A (en) 1971-10-21 1977-08-23 American Cyanamid Company Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
US3932452A (en) 1975-02-07 1976-01-13 Morton-Norwich Products, Inc. 1-Arylmethyl-2-imidazolidinones
US5869481A (en) 1995-09-05 1999-02-09 Arzneitmittelwerk Dresden G.M.B.H. Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19532668A1 (en) 1995-09-05 1997-03-06 Dresden Arzneimittel Novel, anticonvulsant 1-ar (alk) yl-imidazolin-2-ones which contain a disubstituted amine radical in the 4-position, and process for their preparation
DE19721580A1 (en) * 1997-05-23 1998-11-26 Dresden Arzneimittel Use of 1-ar (alk) yl-imidazolin-2-one for the treatment of anxiety and tension
WO1999000346A1 (en) 1997-06-26 1999-01-07 Board Of Regents, The University Of Texas System Synthesis of dihydrohonokiol compositions
JP4669095B2 (en) 1999-07-19 2011-04-13 太陽化学株式会社 Composition for suppressing behavioral problems in pets
PT1870100E (en) 2002-03-07 2012-04-17 Boehringer Ingelheim Int Ethyl 3-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1h-benzimidazole-5-carbonyl)-2-pyridylamino)propionate methansulfonate
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10339862A1 (en) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis
BR112014003117A2 (en) 2011-08-12 2017-06-13 Boehringer Ingelheim Vetmedica Gmbh funny (if) current inhibitors for use in a method of treatment and prevention of feline heart failure
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals

Also Published As

Publication number Publication date
ES2316808T3 (en) 2009-04-16
TWI324067B (en) 2010-05-01
EP2845594B1 (en) 2022-02-23
DE60325496D1 (en) 2009-02-05
SI1553952T1 (en) 2009-04-30
CA2727722C (en) 2013-05-28
AU2003273978A1 (en) 2004-05-04
HRP20050322A2 (en) 2006-05-31
ES2908453T3 (en) 2022-04-29
CN1726040A (en) 2006-01-25
EP2036563A1 (en) 2009-03-18
CN1726040B (en) 2010-05-12
CA2501772C (en) 2011-08-23
DK1553952T3 (en) 2009-04-20
HRP20050322B1 (en) 2013-12-06
US20050070537A1 (en) 2005-03-31
FR22C1033I1 (en) 2022-09-09
PT2845594T (en) 2022-03-09
KR20050056237A (en) 2005-06-14
US20130065898A1 (en) 2013-03-14
KR20110063843A (en) 2011-06-14
ATE418337T1 (en) 2009-01-15
CA2501772A1 (en) 2004-04-22
SI2845594T1 (en) 2022-04-29
EP1553952B1 (en) 2008-12-24
US8859540B2 (en) 2014-10-14
CN101890019A (en) 2010-11-24
JP6249812B2 (en) 2017-12-20
LU92238I9 (en) 2019-01-09
PT1553952E (en) 2009-02-10
JP4694202B2 (en) 2011-06-08
WO2004032938A1 (en) 2004-04-22
CY2013031I2 (en) 2015-11-04
CY1125103T1 (en) 2023-01-05
HRP20200207A2 (en) 2020-07-24
CY2013031I1 (en) 2015-11-04
NZ539864A (en) 2007-11-30
BR0315225A (en) 2005-08-23
PL374603A1 (en) 2005-10-31
AR041573A1 (en) 2005-05-18
BE2013C046I2 (en) 2022-08-09
AU2003273978B2 (en) 2009-07-23
JP2014080449A (en) 2014-05-08
PL238776B1 (en) 2021-10-04
US20150072983A1 (en) 2015-03-12
LU92238I2 (en) 2013-09-03
CY1109961T1 (en) 2014-09-10
US20160367562A1 (en) 2016-12-22
HUS1300035I1 (en) 2017-10-30
JP2011068685A (en) 2011-04-07
JP2016104817A (en) 2016-06-09
AU2009225322A1 (en) 2009-11-05
TW200503726A (en) 2005-02-01
DK2845594T3 (en) 2022-03-07
PL214702B1 (en) 2013-09-30
FR13C0044I1 (en) 2013-08-30
HRP20090667A2 (en) 2010-07-31
TWI424849B (en) 2014-02-01
HK1085920A1 (en) 2006-09-08
KR101110587B1 (en) 2012-02-15
JP2006503873A (en) 2006-02-02
US8962617B2 (en) 2015-02-24
EP2845594A1 (en) 2015-03-11
TW201010706A (en) 2010-03-16
HRP20090667B1 (en) 2021-06-11
US20080027057A1 (en) 2008-01-31
MXPA05003663A (en) 2005-06-08
US9469611B2 (en) 2016-10-18
CA2727722A1 (en) 2004-04-22
EP1553952A1 (en) 2005-07-20
HUS2200036I1 (en) 2022-08-28
ZA200502245B (en) 2005-11-30
PL397320A1 (en) 2012-02-13

Similar Documents

Publication Publication Date Title
FR13C0044I2 (en) USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF CANINE EPILEPSY
FR2854074B1 (en) USE OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS
FR13C0029I1 (en) COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
FR13C0060I2 (en) FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYLUREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS
FR2846870B1 (en) OSTEOSYNTHESIS EQUIPMENT FOR THE TREATMENT OF A "LONG" CUBITUS
FR2840804B1 (en) SYSTEM FOR THE TREATMENT OF OBESITY AND IMPLANT FOR SUCH A SYSTEM
CH1143977H1 (en) 2-Oxy-benzoxazine-4-ones for the treatment of obesity
MA27395A1 (en) USE OF PREBIOTICS FOR THE TREATMENT AND PREVENTION OF HYPER-GLYCEMIC SYNDROMES
DE60204951D1 (en) CCR5 ANTAGONISTS USE FOR THE TREATMENT OF AIDS
DZ3014A1 (en) Medicines for the treatment of hypertension.
DE60238765D1 (en) CARBAMATE COMPOUNDS FOR THE TREATMENT OF PAIN
FR2860154B1 (en) COMPOSITION FOR THE TREATMENT OF MALE BREATH
FR2835851B1 (en) COMPOSITION FOR THE TREATMENT OF MAGNESIUM ALLOYS
MA25852A1 (en) METHOD FOR THE TREATMENT OF INFLAMMATION.
MA26117A1 (en) NEW COMPOUND FOR THE TREATMENT OF IMPOTENCE
DE60005685D1 (en) OXAZINOCARBAZOLE FOR THE TREATMENT OF CNS DISEASES
FR2834887B1 (en) USE OF ARTEMIA EXTRACT FOR THE TREATMENT OF OLD SKIN
ATE391507T1 (en) S-METHYL-DIHYDRO-ZIPRASIDONE FOR THE TREATMENT OF SCHIZOPHRENIA
FR2844815B3 (en) SAFETY COVER FOR SEWERS
FR2849599B1 (en) USE OF KYNURENINE-3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES
FR2843015B1 (en) IMPLANT FOR THE TREATMENT OF PRESBYOPIA
FR2852252B1 (en) IMPLANTABLE VALVE FOR THE TREATMENT OF HYDROCEPHALY
FR2801508B1 (en) USE OF HMG COA-REDUCTASE INHIBITORS FOR THE TREATMENT OF SEBORRHEA
FR2832429B1 (en) IMPROVED WORKPIECE DEVICE FOR ELECTROLYTIC TREATMENT
FR2833967B1 (en) USE OF LACTIC BACTERIA FOR THE PRODUCTION OF ALPHA-CETOGLUTARATE